Search

Author/Creator Hagerman, L.

1. Optimal dosing of a novel PLK4 inhibitor nested in a phase II study of CFI-400945 in patients with Advanced/Metastatic Breast Cancer (MBC): Canadian Cancer Trials Group (CCTG) IND.237. (October 2022)

Authors:
Rushton, M.; Cescon, D.; Hilton, J.; Bedard, P.; Blanchette, P.; Bashir, A.; Pezo, R.; Kumar, V.; Ng, T.; Awan, A.; Lott, A.; Raphael, J.A.; Hagerman, L.; Bray, M.; Muyot, L.; Fuentes Antras, J.; Seymour, L.; Tu, D.; Gaudreau, P.O.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S31
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search